The latest price target for Halozyme Therapeutics (NASDAQ:HALO) was reported by Benchmark on August 8, 2024. The analyst firm set a price target for $60.00 expecting HALO to fall to within 12 months (a possible -5.51% downside). 36 analyst firms have reported ratings in the last year.

The latest analyst rating for Halozyme Therapeutics (NASDAQ:HALO) was provided by Benchmark, and Halozyme Therapeutics reiterated their buy rating.

The last upgrade for Halozyme Therapeutics Inc happened on May 10, 2023 when Piper Sandler raised their price target to $46. Piper Sandler previously had a neutral for Halozyme Therapeutics Inc.

The last downgrade for Halozyme Therapeutics Inc happened on June 7, 2024 when Piper Sandler changed their price target from $48 to $51 for Halozyme Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Halozyme Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Halozyme Therapeutics was filed on August 8, 2024 so you should expect the next rating to be made available sometime around August 8, 2025.

While ratings are subjective and will change, the latest Halozyme Therapeutics (HALO) rating was a reiterated with a price target of $60.00 to $60.00. The current price Halozyme Therapeutics (HALO) is trading at is $63.50, which is out of the analyst’s predicted range.